Essential drug prices in Pakistan jumped nearly 50% in 2024, leaving many patients unable to afford life-saving treatments [1].
This crisis threatens the stability of the national healthcare system and places an unsustainable financial burden on the most vulnerable populations. As costs climb, the gap between available medical care and patient affordability widens, particularly in urban centers.
Price increases are most acute in major cities, including Lahore, Karachi, and Peshawar [2, 3]. Public hospitals and patients are struggling to maintain treatment regimens as the cost of procurement rises. Experts said prices will rise another 30% to 40% in 2025 [1].
Several systemic factors have converged to create this instability. A weakening rupee and soaring inflation have increased the cost of importing raw materials and finished pharmaceuticals [1, 2, 3]. These economic pressures are compounded by global supply disruptions and the deregulation of non-essential medicines [1, 2, 3].
Weak price controls have further allowed costs to climb without sufficient government intervention [1, 2, 3]. The resulting shortages have pushed patients to the brink, as essential medications become scarce or prohibitively expensive in the open market [2, 3].
Healthcare providers in the affected cities said that the inability to access affordable medicine is leading to interrupted treatments for chronic conditions. The combination of currency devaluation and regulatory gaps has created a volatile environment for both the pharmaceutical industry and the public [1, 2, 3].
“Essential drug prices in Pakistan jumped nearly 50% in 2024”
The convergence of currency devaluation and weak regulatory oversight has transformed a fiscal crisis into a public health emergency. By allowing essential drug prices to fluctuate with inflation and exchange rates, Pakistan faces a systemic risk where basic healthcare becomes a luxury, potentially increasing mortality rates for treatable conditions.
